Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANWARFIN.
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
For therapeutic anticoagulation, administer intravenous bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour, adjusted to maintain aPTT 1.5-2.5 times control. For prophylaxis, 5,000 units subcutaneously every 8-12 hours.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
Mean terminal half-life 1.5 hours (range 1-2 hours) at therapeutic doses; dose-dependent (nonlinear) due to saturable clearance; prolonged in renal impairment (up to 3-6 hours) and hepatic disease.
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Primarily hepatic and reticuloendothelial system metabolism; renal excretion of metabolites accounts for <50% of clearance; minimal biliary/fecal elimination.
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticoagulant
Anticoagulant